FibroScan® by echosens
The non-invasive solution for comprehensive management of liver health
Learn more
Liver Health Management
Advancing Liver Health Management for all.
Echosens is introducing the LHM platform, an innovative cloud-based solution which assists clinicians in providing accessible, comprehensive liver care for their patients.
The LHM platform is a digital solution with an ecosystem for continuous monitoring
and proactive management of liver disease.
Streamline your FibroScan® experience
Automate the transfer of FibroScan® results to the LHM platform
to help you make data-driven decisions
Enhance examinations with FibroScan® with Scores
and interpretation tools
Access tools, resources, and clinical care pathways to help
monitor and manage liver disease
A Solution to Support Clinical Decisions
Echosens developed the LHM to provide a digital solution with an ecosystem to support clinical decisions for physicians.
Patient management
- Automatic transfer of FibroScan® results to the LHM
- Remote interpretation
- Worklist synchronization between the FibroScan® and
the LHM
Scores interpretation
Enhancing FibroScan® liver disease assessment with biological markers.
Additional tools and resources
- Secure data transfer and storage
- No FibroScan® device update required
- Easy to configure and connect
- Provides resources to assist you in your FibroScan® daily practice
- Access to Echosens Academy
Elevate the way you manage liver health
LHM platform is available with FibroScan® devices.
Liver Health Management is endorsed by healthcare professionals
Now, Echosens has the Liver Health Management platform where it makes it very user-friendly, even for someone who is not a liver specialist. When we do a FibroScan® exam and generate a report, it’s easy to send it to the referral who sent us the patient. They are able to scan it into their EMR and read and interpret what the values mean. This is more personal and easier to follow.
The new cloud-based Liver Health Management platform has been very beneficial in streamlining our clinical process. The ability to to easily access and calculate the FAST and Fib-4 Scores to produce a consolidated report alongside the FibroScan® examination results is a great tool for our GP referrals and allows easy interpretation. Our patients also love the fact they can track their liver health with the exam history graph.
Already a LHM platform user?
The LHM platform is currently available only in the United States and some European countries. You can contact us to know more.
The FibroScan® device (Models: 530 Compact, 430 Mini+ and 630 Expert) is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography™ (VCTE™) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP™)* at 3.5 MHz. FibroScan® 630 Expert is also intended to measure spleen stiffness using VCTE™ at 100 Hz shear wave frequency. FibroScan liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid for the clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided. *CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available with SmartExam capability. FibroScan Gateway is a Non-Device Medical Device Data Systems (MDDS) and Interpretation Guide (available on myFibroScan application) is a Non-Device Clinical Decision Support (CDS) that meet the criteria outlined in section 520(o) (1)(E) of the FD&C Act. According to the Federal Food, Drug, and Cosmetic Act (21 CFR 880.6310). Fast, Agile 3+ and Agile 4 Products are registered class 1 devices (FDA). Fast calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of NAFLD as being at risk for active fibrotic NASH (NASH+NAS≥4+F≥2). It was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of NAFLD as having advanced fibrosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Agile 4 calculator is a tool for clinicians, computed from LSM (obtained from FibroScan device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of NAFLD as having cirrhosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Fast, Agile 3+ and Agile 4 are presented as educational services intended for licensed healthcare professionals. While these scores are about specific medical and health issues,they are not a substitute for or a replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
